Products and documentation listed and referenced here are not available to customers within the United States.

Initially, we started off as a pioneer in DNA methylation, exploiting this natural phenomenon with our proprietary technologies as a rich source of biomarkers. Today, we have come of age and are developing and commercializing molecular diagnostic tests detecting our proprietary DNA methylation biomarkers, thereby answering specific high need medical diagnostic questions. Our Epi proColon and Epi proLung tests help doctors on a daily basis in diagnosing cancer earlier and with more certainty.

Our product pipeline is based on programs in colorectal, lung and prostate cancer, each with several product opportunities. In each of these products, we focus on maximizing the value of our validated biomarkers for further clinical applications.

While we are dedicated to developing molecular diagnostic tests for cancer, we have continuously improved our proprietary technology to maintain leadership in DNA methylation-based diagnostics.